Alumis Director Makes Major $10M Share Purchase as Stock Soars Over 400% in Recent Months

Srinivas Akkaraju, Director at clinical-stage biotech company Alumis (NASDAQ: ALMS), has made a substantial open-market acquisition of 588,235 shares valued at approximately $10.0 million on January 9, 2026. The transaction reflects significant confidence in the company’s trajectory, occurring as the stock has demonstrated impressive momentum in recent trading periods.

Transaction Details and Structure

The purchase consideration formula breaks down as follows: 588,235 shares were acquired at $17.00 per share, totaling $9,999,995. Notably, the transaction price represented a meaningful discount to subsequent market levels. By January 16, 2026, the stock had climbed to $23.86, indicating the insider captured an advantageous entry point.

All acquired shares are held indirectly through Samsara Opportunity Fund, L.P., with Akkaraju exercising voting and investment power as the fund operates through its general partner structure. This arrangement aligns with the director’s existing holding pattern, as his previously disclosed indirect position totaled 6,345,219 shares across Samsara Opportunity Fund and Samsara BioCapital fund.

The 588,235-share acquisition increased his indirect holdings by 46.49% in a single transaction, marking one of the largest individual purchases on record for this insider. Historically, Akkaraju’s median trade size hovered around 186,000 shares, making this accumulation substantially above typical activity levels.

Rapid Accumulation Amid Strong Price Performance

This significant purchase follows a series of incremental share acquisitions over the preceding two months, suggesting the director is strategically building exposure as capacity permits. The timing is notable given the broader stock performance context: Alumis shares have appreciated approximately 206% over the preceding year, with an especially dramatic surge of over 400% within the most recent three-month window.

Insider buying at scale often signals management’s conviction regarding future business developments. In this case, the timing coincides with meaningful clinical progress in the company’s pipeline.

Clinical Pipeline Advances

Alumis operates as a research-driven clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and neuroinflammatory diseases. The company’s platform centers on advanced TYK2 inhibitor technology, with lead candidates ESK-001 and A-005 representing core pipeline assets.

Recently, the company announced positive Phase 3 trial results for envudeucitinib, an oral therapeutic candidate targeting psoriasis treatment. The clinical data proved compelling: approximately 65% of patients receiving the treatment achieved at least 90% improvement in their Psoriasis Area and Severity Index (PASI) scores. More impressively, 40% of treated patients demonstrated 100% improvement in PASI scores following 24 weeks of therapy.

These efficacy rates position envudeucitinib as a potentially differentiated asset in the psoriasis treatment landscape, addressing a significant market opportunity with high unmet medical need.

Company Valuation and Market Position

As of the transaction date (January 9, 2026), Alumis commanded a market capitalization of $2.49 billion, with trailing twelve-month revenue of $22.12 million. The company’s valuation reflects investor expectations for successful clinical progression and eventual commercialization of its therapeutic pipeline.

Alumis targets healthcare providers, specialists, and biopharmaceutical partners addressing autoimmune and neurodegenerative conditions. The company’s competitive positioning rests on innovation in targeted therapeutics and a commitment to advancing transformative medicines for complex immune-related disorders.

Investment Implications

From an investor standpoint, insider purchasing of this magnitude—particularly when directors commit substantial personal capital at premium valuations—typically reflects confidence in near-term catalysts and medium-term value creation potential. Akkaraju’s decision to increase exposure by nearly 47% in a single transaction suggests he anticipates continued positive developments.

The convergence of strong recent clinical data, momentum in stock price appreciation, and scaled insider accumulation presents multiple reinforcing signals regarding market sentiment toward Alumis’ prospects. However, investors should recognize that clinical-stage biotechnology companies remain inherently speculative, with regulatory approval and commercialization success remaining uncertain.